Publicacións en colaboración con investigadores/as de University Hospital of Zurich (31)

2024

  1. Heart failure in Europe: Guideline-directed medical therapy use and decision making in chronic and acute, pre-existing and de novo, heart failure with reduced, mildly reduced, and preserved ejection fraction – the ESC EORP Heart Failure III Registry

    European Journal of Heart Failure

  2. Left ventricular ejection fraction digit bias and reclassification of heart failure with mildly reduced vs reduced ejection fraction based on the 2021 definition and classification of heart failure

    American Heart Journal, Vol. 267, pp. 52-61

2023

  1. Comprehensive characterization of non-cardiac comorbidities in acute heart failure: an analysis of ESC-HFA EURObservational Research Programme Heart Failure Long-Term Registry

    European journal of preventive cardiology, Vol. 30, Núm. 13, pp. 1346-1358

  2. How does age affect outcomes after left ventricular assist device implantation: results from the PCHF-VAD registry

    ESC Heart Failure, Vol. 10, Núm. 2, pp. 884-894

  3. Hyponatraemia and changes in natraemia during hospitalization for acute heart failure and associations with in-hospital and long-term outcomes – from the ESC-HFA EORP Heart Failure Long-Term Registry

    European Journal of Heart Failure, Vol. 25, Núm. 9, pp. 1571-1583

  4. Participation in a clinical trial is associated with lower mortality but not lower risk of HF hospitalization in patients with heart failure: observations from the ESC EORP Heart Failure Long-Term Registry

    European Heart Journal, Vol. 44, Núm. 17, pp. 1526-1529

  5. Prevalence, characteristics and prognostic impact of aortic valve disease in patients with heart failure and reduced, mildly reduced, and preserved ejection fraction: An analysis of the ESC Heart Failure Long-Term Registry

    European Journal of Heart Failure, Vol. 25, Núm. 7, pp. 1049-1060

  6. Prevalence, clinical characteristics and outcomes of heart failure patients with or without isolated or combined mitral and tricuspid regurgitation: An analysis from the ESC-HFA Heart Failure Long-Term Registry

    European Journal of Heart Failure, Vol. 25, Núm. 7, pp. 1061-1071

  7. Rationale and design of the ESC Heart Failure III Registry – Implementation and discovery

    European Journal of Heart Failure, Vol. 25, Núm. 12, pp. 2316-2330

  8. Sex-related differences in left ventricular assist device utilization and outcomes: results from the PCHF-VAD registry

    ESC Heart Failure, Vol. 10, Núm. 2, pp. 1054-1065

2022

  1. A comprehensive characterization of acute heart failure with preserved versus mildly reduced versus reduced ejection fraction – insights from the ESC-HFA EORP Heart Failure Long-Term Registry

    European Journal of Heart Failure, Vol. 24, Núm. 2, pp. 335-350

  2. Impact of progressive aortic regurgitation on outcomes after left ventricular assist device implantation

    Heart and Vessels, Vol. 37, Núm. 12, pp. 1985-1994

  3. Improved survival of left ventricular assist device carriers in Europe according to implantation eras: results from the PCHF-VAD registry

    European Journal of Heart Failure, Vol. 24, Núm. 7, pp. 1305-1315

2021

  1. Guidance on the management of left ventricular assist device (LVAD) supported patients for the non-LVAD specialist healthcare provider: executive summary

    European Journal of Heart Failure, Vol. 23, Núm. 10, pp. 1597-1609

2020

  1. Association between loop diuretic dose changes and outcomes in chronic heart failure: observations from the ESC-EORP Heart Failure Long-Term Registry

    European Journal of Heart Failure, Vol. 22, Núm. 8, pp. 1424-1437

  2. Is heart failure misdiagnosed in hospitalized patients with preserved ejection fraction? From the European Society of Cardiology - Heart Failure Association EURObservational Research Programme Heart Failure Long-Term Registry

    ESC Heart Failure, Vol. 7, Núm. 5, pp. 2098-2112

  3. Levosimendan Efficacy and Safety: 20 Years of SIMDAX in Clinical Use

    Journal of cardiovascular pharmacology, Vol. 76, Núm. 1, pp. 4-22

  4. Levosimendan Efficacy and Safety: 20 years of SIMDAX in Clinical Use

    Cardiac Failure Review, Vol. 6

  5. Sex- and age-related differences in the management and outcomes of chronic heart failure: an analysis of patients from the ESC HFA EORP Heart Failure Long-Term Registry

    European Journal of Heart Failure, Vol. 22, Núm. 1, pp. 92-102

  6. Unravelling the interplay between hyperkalaemia, renin–angiotensin–aldosterone inhibitor use and clinical outcomes. Data from 9222 chronic heart failure patients of the ESC-HFA-EORP Heart Failure Long-Term Registry

    European Journal of Heart Failure, Vol. 22, Núm. 8, pp. 1378-1389